Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the applic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rini, Brian I, Brugarolas, James, Atkins, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008164/
https://www.ncbi.nlm.nih.gov/pubmed/36898737
http://dx.doi.org/10.1136/jitc-2022-006361
_version_ 1784905694534696960
author Rini, Brian I
Brugarolas, James
Atkins, Michael B
author_facet Rini, Brian I
Brugarolas, James
Atkins, Michael B
author_sort Rini, Brian I
collection PubMed
description Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.
format Online
Article
Text
id pubmed-10008164
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-100081642023-03-13 Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma Rini, Brian I Brugarolas, James Atkins, Michael B J Immunother Cancer Commentary Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice. BMJ Publishing Group 2023-03-10 /pmc/articles/PMC10008164/ /pubmed/36898737 http://dx.doi.org/10.1136/jitc-2022-006361 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Rini, Brian I
Brugarolas, James
Atkins, Michael B
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
title Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
title_full Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
title_fullStr Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
title_full_unstemmed Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
title_short Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
title_sort navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008164/
https://www.ncbi.nlm.nih.gov/pubmed/36898737
http://dx.doi.org/10.1136/jitc-2022-006361
work_keys_str_mv AT rinibriani navigatingandadaptingcareintegratingimmunotherapyantiangiogenictherapyandcombinationsinpatientswithadvancedrenalcellcarcinoma
AT brugarolasjames navigatingandadaptingcareintegratingimmunotherapyantiangiogenictherapyandcombinationsinpatientswithadvancedrenalcellcarcinoma
AT atkinsmichaelb navigatingandadaptingcareintegratingimmunotherapyantiangiogenictherapyandcombinationsinpatientswithadvancedrenalcellcarcinoma

Ejemplares similares